Literature DB >> 25978000

Mad2 Inhibitor-1 (M2I-1): A Small Molecule Protein-Protein Interaction Inhibitor Targeting the Mitotic Spindle Assembly Checkpoint.

Johanna Kastl1, Joachim Braun2, Andreas Prestel2, Heiko M Möller2,3, Thomas Huhn2, Thomas U Mayer1.   

Abstract

The genetic integrity of each organism depends on the faithful segregation of its genome during mitosis. To meet this challenge, a cellular surveillance mechanism, termed the spindle assembly checkpoint (SAC), evolved that monitors the correct attachment of chromosomes and blocks progression through mitosis if corrections are needed. While the central role of the SAC for genome integrity is well established, its functional dissection has been hampered by the limited availability of appropriate small molecule inhibitors. Using a fluorescence polarization-based screen, we identify Mad2 inhibitor-1 (M2I-1), the first small molecule inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the SAC. Based on computational and biochemical analyses, we propose that M2I-1 disturbs conformational dynamics of Mad2 critical for complex formation with Cdc20. Cellular studies revealed that M2I-1 weakens the SAC response, indicating that the compound might be active in cells. Thus, our study identifies the SAC specific complex formation between Mad2 and Cdc20 as a protein-protein interaction that can be targeted by small molecules.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25978000     DOI: 10.1021/acschembio.5b00121

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  8 in total

1.  The kinetochore-dependent and -independent formation of the CDC20-MAD2 complex and its functions in HeLa cells.

Authors:  Jianquan Li; Nanmao Dang; Daniel James Wood; Jun-Yong Huang
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

Review 2.  Activating the Anaphase Promoting Complex to Enhance Genomic Stability and Prolong Lifespan.

Authors:  Troy A A Harkness
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

3.  M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s.

Authors:  Jianquan Li; Nanmao Dang; Nuria Martinez-Lopez; Paul A Jowsey; Dong Huang; Robert N Lightowlers; Fei Gao; Jun-Yong Huang
Journal:  Cell Div       Date:  2019-06-15       Impact factor: 5.130

4.  Bio-Based Coating Materials Derived from Acetoacetylated Soybean Oil and Aromatic Dicarboxaldehydes.

Authors:  Zhiyuan Cao; Fei Gao; Jinze Zhao; Xiao Wei; Qian Cheng; Jiang Zhong; Cong Lin; Jinbing Shu; Changqing Fu; Liang Shen
Journal:  Polymers (Basel)       Date:  2019-11-04       Impact factor: 4.329

Review 5.  Understanding How Genetic Mutations Collaborate with Genomic Instability in Cancer.

Authors:  Laura J Jilderda; Lin Zhou; Floris Foijer
Journal:  Cells       Date:  2021-02-06       Impact factor: 6.600

6.  Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma.

Authors:  Terra G Arnason; Valerie MacDonald-Dickinson; Matthew Casey Gaunt; Gerald F Davies; Liubov Lobanova; Brett Trost; Zoe E Gillespie; Matthew Waldner; Paige Baldwin; Devon Borrowman; Hailey Marwood; Frederick S Vizeacoumar; Franco J Vizeacoumar; Christopher H Eskiw; Anthony Kusalik; Troy A A Harkness
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 7.  The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.

Authors:  Cordell VanGenderen; Troy Anthony Alan Harkness; Terra Gayle Arnason
Journal:  Aging (Albany NY)       Date:  2020-08-15       Impact factor: 5.682

8.  Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines.

Authors:  Natalia Pajuelo-Lozano; Sonia Alcalá; Bruno Sainz; Rosario Perona; Isabel Sanchez-Perez
Journal:  Theranostics       Date:  2020-07-25       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.